Key points from article :
Cassava's open-label study for Alzheimer’s disease (AD) candidate simufilam.
Six months’ treatment with the oral, small molecule not just stabilized but improved cognition and behavior scores in AD patients.
Cognition scores for the same patients rose 10%.
Anxiety, delusions and agitation, all dementia-related behavior, showed a 29% mean improvement.
Positive data propel simufilam into a phase III study in the second half of 2021.
Restore normal shape and function of altered filamin A, a scaffolding protein, in the brain.
“In Alzheimer’s, the filament misfolds and allows downstream pathologies..,” Remi Barbier, President and CEO, Cassava Sciences.
Phase IIb data showed significantly reduced levels of HMGB1 protein in cerebrospinal fluid (CSF).
Improved the integrity of the blood-brain barrier, with CSF IgG decrease.
Albumin ratio improved by about 5 and 7 points for patients treated with 50 mg and 100 mg.
Share prices of company rose a staggering 141.15%.
